Investigational drug · Phase 3
Ezabenlimab
Also called: BI 754091
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Cancer, Neoplasm Metastasis, Advanced Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
27
Any phase or sponsor naming "Ezabenlimab"
First trial start
2019
Mar 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ezabenlimab", any sponsor or status.
- Phase 122
Conditions studied
As listed on its trial records.
- Advanced Cancer
- Neoplasm Metastasis
- Advanced Tumors
- Metastatic Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ezabenlimab" as an intervention, largest first.
Boehringer IngelheimBoehringer Ingelheim
NCT03468426 · 252 participants · Start Jul 5, 2018 · Primary completion Jul 31, 2024
Drug: BI 836880; Ezabenlimab · For: Non-squamous, Non-Small-Cell Lung Cancer; Neoplasms
Sites: Birmingham, Alabama; Beverly Hills, California; Atlanta, Georgia · 43 sites in all
- Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid TumoursPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT03697304 · 211 participants · Start Mar 19, 2019 · Primary completion Dec 3, 2024
Drug: Ezabenlimab; BI 754111 and 1 more · For: Neoplasm Metastasis; Advanced Tumors; Metastatic Solid Tumors
Sites: La Jolla, California; Fort Myers, Florida; St. Petersburg, Florida · 17 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03156114 · 172 participants · Start Jun 13, 2017 · Primary completion Mar 9, 2023
Drug: Ezabenlimab; BI 754111 · For: Neoplasms; Carcinoma, Non-Small-Cell Lung
Sites: Miami, Florida; Sarasota, Florida; Hackensack, New Jersey · 15 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04958239 · 151 participants · Start Oct 18, 2021 · Primary completion Apr 27, 2026
Drug: BI 765179; Ezabenlimab and 1 more · For: Neoplasms
Sites: Tucson, Arizona; Beverly Hills, California; Chapel Hill, North Carolina · 48 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03433898 · 146 participants · Start Feb 23, 2018 · Primary completion Jul 20, 2023
Drug: Ezabenlimab; BI 754111 · For: Neoplasms
Sites: Chiba, Kashiwa, Japan; Kanagawa, Yokohama, Japan; Saitama, Kitaadachi-gun, Japan · 13 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03964233 · 119 participants · Start Jun 20, 2019 · Primary completion Sep 5, 2024
Drug: BI 907828; ezabenlimab and 1 more · For: Neoplasms
Sites: Santa Monica, California; New Haven, Connecticut; Athens, Georgia · 23 sites in all
- Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal CancerActive, not recruiting
Amal TherapeuticsIndustry
NCT04046445 · 96 participants (planned) · Start Jul 22, 2019 · Primary completion May 31, 2025
Drug: ATP128; BI 754091 and 1 more · For: Colorectal Cancer; MSS; Stage IV Colon Cancer and 3 more
Sites: Scottsdale, Arizona; Los Angeles, California; Aurora, Colorado · 12 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07851103 · 90 participants (planned) · Start Nov 10, 2026 · Primary completion Sep 3, 2030
Drug: BI 3968621; ezabenlimab · For: Advanced Solid Tumour
Sites: Sarasota, Florida; Atlanta, Georgia; Philadelphia, Pennsylvania · 10 sites in all
- A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigPivotal-lookingNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07929051 · 68 participants (planned) · Start Mar 4, 2027 · Primary completion Jul 3, 2028
Drug: Obrixtamig; Ezabenlimab and 3 more · For: Advanced Cancer
Sites: Ghent, Belgium; Bordeaux, France; Bron, France · 15 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04752215 · 67 participants · Start May 18, 2021 · Primary completion Nov 19, 2024
Drug: BI 765049; ezabenlimab · For: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- In-human assessment of target engagement and blockade of radiolabeled BI 765063, an anti-SIRPα antibody.
Pouw JEE, Stavenga M, Zwezerijnen GJC, et al. · EJNMMI Res 2026
- Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma - Authors' reply.
Borg C, Kim S · Lancet Oncol 2026
- Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma.
Tyagi B, Toppo L, Biradar A · Lancet Oncol 2026
- The Second Mitochondria-Derived Activator of Caspases Mimetic BI 891065 in Patients With Advanced Solid Tumors: Results From Two Phase I Studies.
Patel MR, Hamilton EP, George B, et al. · Cancer Med 2025
- Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.
Kim S, Boustani J, Iseas S, et al. · Lancet Oncol 2025
- Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Harrington K, Kitano S, Gambardella V, et al. · Future Oncol 2025
Also in development for Advanced Cancer
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- ALK201Phase 22 trials
Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors
- CVM-1118TRX-818Phase 22 trials
TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- Personalized Neoantigen Peptide VaccinePhase 22 trials
Seqker Biosciences, Inc. · Solid Tumors, Advanced Cancer, Recurrent Cancer
- TST001Phase 22 trials
Transcenta Therapeutics (Hangzhou) Co., Ltd. · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- APL-101Phase 21 trial
Apollomics Inc. · Solid Tumors, Advanced Cancer, Renal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.